Amended and Restated License Agreement



 Exhibit 10.32 
 [*] indicates that a confidential portion of the text of this agreement has been omitted. 
 AMENDED AND
RESTATED 
 LICENSE AGREEMENT 
 This AMENDED AND RESTATED LICENSE AGREEMENT (this “Agreement”), dated effective as of October 27, 2006 (the “Effective Date of this Agreement”), is entered into by and between XOMA Ireland Limited, a
company with limited liability organized under the laws of the Republic of Ireland having offices at Shannon Airport House, Shannon, County Clare, Ireland (with its Affiliates, “XOMA”) and DYAX Corp., a corporation organized under
the laws of the State of Delaware having offices at 300 Technology Square, Cambridge, Massachusetts 02139, U.S.A. (with its Affiliates, “DYAX”). 
 BACKGROUND 
 A. XOMA is the owner or exclusive licensee of certain patent rights and know-how
relating to bacterial cell expression, and DYAX wishes to acquire non-exclusive licenses under such patent rights and know-how; and 
 B.
DYAX is the owner or exclusive licensee of certain patent rights relating to phage display technologies (generally known as the Ladner and related patent rights), and XOMA wishes to acquire non-exclusive licenses under such patent rights; and

 C. XOMA and DYAX previously executed a License Agreement, dated effective as of October 16, 2002 (the “Effective Date of the
Original Agreement”), under which (i) XOMA granted to DYAX certain non-exclusive licenses to engage in certain research, development and commercial activities, and (ii) DYAX granted to XOMA certain non-exclusive licenses to engage
in certain research, development and commercial activities (the “Original Agreement”); and 
 D. XOMA has requested that
DYAX provide XOMA with certain quantities of its most recently developed antibody phage display libraries to use in connection with the license granted herein by DYAX to XOMA; and 
 E. DYAX is willing to provide such libraries to XOMA if the terms of the Original Agreement are amended and restated as set forth herein. 
 NOW, THEREFORE, in consideration of the promises and the mutual covenants hereinafter recited, the parties agree that, from and after the date hereof,
the Original Agreement shall be amended and restated as follows: 







 ARTICLE 1. DEFINITIONS 
 In this Agreement, the following terms shall have the meanings set forth in this Article. 
 1.1 “Affiliate” means any corporation or other entity which is directly or indirectly controlling, controlled by or under common control
with a party hereto. For purposes of this Agreement, “control” (including, with correlative meanings, the terms “controlled” and “controlling”) means the possession, directly or indirectly, of the
power to direct or cause the direction of the management or policies of the subject corporation or other entity, whether through the ownership of voting securities, by agreement or otherwise. 
 1.2 “Antibody Phage Display” means the authorized use of Licensed Antibody Phage Display Materials to conduct Research and Development.

 1.3 “Change in Control” means, with respect to Dyax Corp. or XOMA Ltd., any transaction or series of transactions as a
result of which any person or group (as defined under the U.S. Securities Exchange Act of 1934, as amended) becomes, directly or indirectly, the beneficial owner of more than fifty percent (50%) of the total voting power of such entity’s
equity securities or otherwise gains control of such entity. 
 1.4 “Commercial Antibody Phage Display Business” means, with
respect to immunoglobulin or antibody phage display services, immunoglobulin or antibody phage display libraries, immunoglobulin or antibody phage display products or immunoglobulin or antibody phage display materials, the out-licensing, commercial
manufacture, sale, offer for sale, import for sale or export for sale of such immunoglobulin or antibody phage display services, libraries, products and materials. 
 1.5 “Confidential Information” means any proprietary or confidential information or material disclosed by a party to the other party pursuant to this Agreement, which is (i) disclosed in tangible
form hereunder and is designated thereon as “Confidential” at the time it is delivered to the receiving party, or (ii) disclosed orally hereunder and identified as confidential or proprietary when disclosed and such disclosure of
confidential information is confirmed in writing within thirty (30) days by the disclosing party. 
 1.6 “Development
Partner” means a Third Party from whom a party either in- licenses a target for development and/or commercialization by the in-licensing party or with whom a party shares the economic risk of development or commercialization of a target or
product being developed or commercialized on behalf of the applicable party. 
 1.7 “Dispose” means to transfer, assign,
lease, or in any other fashion dispose of control, ownership or possession, but shall not mean to license or sell. “Disposition” shall have the correlative meaning. 
 1.8 “DYAX Collaborator” means any person or entity who is an authorized end-user of Licensed Antibody Phage Display Materials, the
intended recipient of Licensed Immunoglobulins or Licensed Immunoglobulin Information transferred from DYAX and/or a person or entity on whose behalf DYAX knowingly engages in Antibody Phage Display. Except as expressly set forth on Schedule
2.9(i). 

  

 -2- 








 
no person or entity shall be deemed to be a DYAX Collaborator if such person or entity is engaged in a Commercial Antibody Phage Display Business unless,
pursuant to a written agreement (other than this Agreement), executed after the Effective Date of the Original Agreement, XOMA has granted to such person or entity a valid license or covenant not to sue under the XOMA Patent Rights which explicitly
extends to the activities identified in this third to last sentence of Section 1.8. XOMA shall provide DYAX prompt written notice of those written agreements or covenants not to sue which satisfy the requirements of the prior sentence. No
person or entity may claim the status of DYAX Collaborator with respect to any acts or activities which are unrelated to the use of Licensed Antibody Phage Display Materials provided by DYAX. 
 1.9 “DYAX Patent Rights” means the patent applications and patents listed on Schedule 1.9 hereto and, solely to the extent any
Valid Claim would cover or be included in the license grants provided for herein, all divisions, continuations, continuations-in-part, applications claiming priority thereto, and substitutions thereof; all foreign patent applications corresponding
to the preceding applications; all U.S. and foreign patents issuing on any of the preceding applications, including extensions, reissues and re-examinations; and any other patent rights owned or licensed by DYAX, whether now existing or obtained in
the future, which DYAX has the right to license or sublicense and which would be infringed by the activities of XOMA contemplated hereunder but for this Agreement. DYAX Patent Rights shall also include (i) any improvements of the foregoing that
are owned or controlled by DYAX and (ii) any patents or patent applications, whether now existing or obtained in the future, owned or controlled by DYAX containing a claim that is dominating over the foregoing patent rights (i.e., is
necessarily infringed by the practicing of a claim in one of the foregoing applications). 
 1.10 “First Commercial Sale”
means the initial transfer by DYAX (either directly or through a Third Party, including without limitation any joint venture or similar arrangement in which DYAX and/or a Development Partner of DYAX is a participant) of a Product for value and not
for demonstration, testing or promotional purposes. 
 1.11 “Immunoglobulin” means any molecule, including without
limitation, full immunoglobulin molecules (e.g., IgG, IgM, IgE, IgA and IgD molecules) and ScFv, Fv and Fab molecules, that has an amino acid sequence by virtue of which it specifically interacts with an antigen and wherein that amino acid sequence
consists essentially of a functionally operating region of an antibody variable region including, without limitation, any naturally occurring or recombinant form of such a molecule. 
 1.12 “Licensed Antibody Phage Display Materials” means (i) any collection or library of polynucleotide sequences, created by and
under the exclusive control of DYAX, which encodes at least one Immunoglobulin and which is contained in filamentous bacteriophage and/or bacteriophage or phagemid cloning vectors capable of propagation in bacteria; or (ii) any collection or
library of bacteriophage, created by or under the exclusive control of DYAX, wherein an Immunoglobulin is expressed as a fusion protein comprising an Immunoglobulin or at least a functionally operating region of an antibody variable region and an
outer surface polypeptide of a bacteriophage. For the avoidance of doubt, and without expanding the definition thereof, specifically excluded from the definition of Licensed Antibody Phage Display Materials are (x) any article of manufacture or
composition of matter suitable for display, 

  

 -3- 








 
expression or secretion of an Immunoglobulin in or from any organism or system other than bacteria and (y) any materials or composition of matter
otherwise meeting the definition of Licensed Antibody Phage Display Materials but created by or under the control of any entity, other than DYAX, engaged in a Commercial Antibody Phage Display Business; provided, that, notwithstanding the
foregoing, any materials or composition of matter otherwise meeting the definition of Licensed Antibody Phage Display Materials but created by or under the exclusive control of a DYAX Collaborator shall constitute Licensed Antibody Phage Display
Materials, but only to the extent derived by such DYAX Collaborator exclusively from Licensed Antibody Phage Display Materials created by or under the exclusive control of DYAX and properly transferred by DYAX to such DYAX Collaborator in accordance
with the applicable provisions of this Agreement and such DYAX Collaborator acknowledges that the transfer restrictions and other provisions hereof apply thereto. 
 1.13 “Licensed Immunoglobulin” means any Immunoglobulin discovered, isolated or characterized by DYAX or a DYAX Collaborator (as defined above) through the use of Licensed Antibody Phage Display
Materials. 
 1.14 “Licensed Immunoglobulin Information” means any data, know-how or other information relating, concerning
or pertaining to a Licensed Immunoglobulin, including, without limitation, data, know-how or other information characterizing or constituting such Licensed Immunoglobulin’s polynucleotide or amino acid sequence, purported function or utility,
antigen binding affinity, or physical or biochemical property. 
 1.15 “Net Sales” means, solely with respect to sales by
DYAX (either directly or through a Third Party, including without limitation any joint venture or similar arrangement in which DYAX and/or a Development Partner of DYAX is a participant), the gross amount invoiced by DYAX (or such joint venture or
similar arrangement) to an independent Third Party less the following items: 
  

	 	(a)	Trade, cash and quantity discounts actually allowed and taken directly with respect to such sales; 

  

	 	(b)	Excises, sales taxes or other taxes imposed upon and paid directly with respect to such sales (excluding national, state or local taxes based income); 

  

	 	(c)	Amounts repaid or credited by reason of rejections, defects, recalls or returns or because of rebates or retroactive price reduction; and 

  

	 	(d)	Freight, transportation and insurance. 

 Net Sales shall not include any
consideration received by DYAX (or any such joint venture or similar arrangement) in respect of the sale, use or other disposition of such Product in a country as part of a clinical trial prior to the receipt of all regulatory approvals required to
commerce full commercial sales of such Product in such country, except sales under “treatment INDs,” “named patient sales,” “compassionate use sales,” or their equivalents pursuant to which DYAX (or any such joint
venture or similar arrangement) is 

  

 -4- 








 
entitled, under applicable laws, regulations and regulatory policies, to recover costs incurred in providing such Product to patients. 
 1.16 “Product” means any composition of matter or article of manufacture, including without limitation any diagnostic, prophylactic or
therapeutic product, which (a) contains a Licensed Immunoglobulin; or (b) was discovered or created by, arose out of or is related to use of Licensed Antibody Phage Display Materials or the conduct of Antibody Phage Display by DYAX or a
DYAX Collaborator; or (c) is sold by or on behalf of DYAX or a DYAX Collaborator under conditions which, if unlicensed, would constitute infringement of the XOMA Patent Rights. 
 1.17 “Research and Development” means the identification, selection, isolation, purification, characterization, study and/or testing of
an Immunoglobulin for any purpose, including, without limitation, any activities relating to the discovery and development of human therapeutic or diagnostic products. Included within the definition of “Research and Development” shall be
all in vitro screening or assays customarily performed in pre-clinical and clinical research and uses associated with obtaining FDA or equivalent agency regulatory approval. Notwithstanding anything to the contrary contained herein,
“Research and Development” shall not include use of the XOMA Expression Technology in commercial or industrial manufacture or any activities solely directed to the creation of such capacities. 
 1.18 “Research Quantities” means those quantities of an Immunoglobulin reasonably required for Research and Development purposes.

 1.19 “Third Party” means any person or entity other than DYAX or XOMA. 
 1.20 “Valid Claim” means (i) a claim of an issued and unexpired patent included within the DYAX Patent Rights or the XOMA Patent
Rights, as the case may be, which has not been held invalid in a final decision of a court of competent jurisdiction from which no appeal may be taken, and which has not been disclaimed or admitted to be invalid or unenforceable through reissue or
otherwise, or (ii) a claim of a pending patent application within the DYAX Patent Rights or the XOMA Patent Rights, as the case may be. 
 1.21 “XOMA Expression Technology” means any method, composition of matter or article of manufacture suitable for the expression of a functional Immunoglobulin in a prokaryote. 
 1.22 “XOMA Field of Use” means all fields. 
 1.23 “XOMA Know-How” means unpatented and/or unpatentable technical information, including ideas, concepts, inventions, discoveries, data, designs, formulas, specifications, procedures for experiments
and tests and other protocols, results of experimentation and testing, fermentation and purification techniques, and assay protocols, whether now existing or obtained in the future, owned by XOMA which XOMA has the right to license or sublicense and
which may be necessary for the practice of the applicable XOMA Patent Rights or which would be misappropriated by the activities of DYAX or the 

  

 -5- 








 
DYAX Collaborators contemplated hereunder but for this Agreement. XOMA Know-How shall not include the XOMA Patent Rights. All XOMA Know-How shall be
confidential information of XOMA. 
 1.24 “XOMA Patent Rights” means the patent applications and patents listed on
Schedule 1.24 hereto and, solely to the extent any Valid Claim would cover or be included in the license grants provided for herein, all divisions, continuations, continuations-in-part, applications claiming priority thereto, and
substitutions thereof; all foreign patent applications corresponding to the preceding applications; all U.S. and foreign patents issuing on any of the preceding applications, including extensions, reissues and re-examinations; and any other patent
rights owned by XOMA which XOMA has the right to license or sublicense and which would be infringed by the activities contemplated hereunder but for this Agreement. XOMA Patent Rights shall also include (i) any improvements of the foregoing
that are owned or controlled by XOMA and (ii) any patents or patent applications, whether now existing or obtained in the future, owned or controlled by XOMA containing a claim that is dominating over the foregoing patent rights (i.e., is
necessarily infringed by the practicing of a claim in one of the foregoing applications). 
 The above definitions are intended to encompass
the defined terms in both the singular and plural forms. 
 ARTICLE 2. XOMA GRANT OF RIGHTS TO DYAX 
 2.1 License Grants. Subject to the other terms and conditions of this Agreement, XOMA hereby grants to DYAX a worldwide, non-exclusive,
non-transferable (other than as provided in Section 9.2) license, without any right to sublicense, under the XOMA Patent Rights and the XOMA Know-How to: 
  

	 	(a)	on its own behalf and on behalf of a DYAX Development Partner or DYAX Collaborator, make or have made Licensed Antibody Phage Display Materials; 

  

	 	(b)	on its own behalf and on behalf of a DYAX Collaborator, transfer Licensed Antibody Phage Display Materials; 

  

	 	(c)	on its own behalf and on behalf of a DYAX Development Partner or DYAX Collaborator, conduct Antibody Phage Display to identify and isolate Licensed Immunoglobulin;


  

	 	(d)	on its own behalf and on behalf of a DYAX Development Partner or DYAX Collaborator, use the XOMA Expression Technology in connection with the use of Licensed Antibody Phage Display
Materials to make or have made Research Quantities of Licensed Immunoglobulin; 

  

	 	(e)	 on its own behalf and on behalf of a DYAX Development Partner or DYAX Collaborator, use Licensed Immunoglobulin or Licensed Immunoglobulin Information to research
and develop, make, have made, use, offer for sale, sell and have 



  

 -6- 









	 	 
sold, import and have imported Products for use in the treatment, prophylaxis, diagnosis or monitoring of a human disease state or condition; and



  

	 	(f)	on its own behalf and on behalf of a DYAX Development Partner, to make, have made, use, offer for sale, sell and have sold, import and have imported Products for use in the
treatment, prophylaxis, diagnosis or monitoring of a human disease state or condition. 

 For the sake of clarity, (i) the
licenses granted in Section 2.1 are personal to DYAX and are to be used on behalf of any DYAX Collaborator or Development Partner of DYAX only in respect of or in connection with the activities that such DYAX Collaborator or Development Partner
of DYAX is engaged in that are the basis for meeting the definition of DYAX Collaborator or Development Partner of DYAX, as the case may be, and not any other activities, and (ii) without limiting the foregoing, the license granted in
Section 2.1(f) is not to be used on behalf of any DYAX Collaborator or any other Third Party that is not a Development Partner of DYAX. 
 2.2 XOMA Transfer to DYAX. Within thirty (30) days of the Effective Date of this Agreement, XOMA shall transfer to DYAX, at a reasonable place and time of DYAX’s direction, the materials identified on Schedule 2.2.

 2.3 Covenant Not To Sue. In partial consideration for the payments set forth in Sections 4.1 and 4.2, XOMA covenants that it shall
not initiate or permit any Third Party over whom it has control to initiate or assist in any way in the initiation or prosecution of any action asserting a claim of infringement under the XOMA Patent Rights or misappropriation of the XOMA Know-How
against DYAX, any Development Partner of DYAX or any DYAX Collaborator solely to the extent reasonably necessary to permit the authorized use of Licensed Antibody Phage Display Materials, Licensed Immunoglobulins or Licensed Immunoglobulin
Information for activities or in a manner otherwise permitted under the provisions of this Agreement. The parties agree that the covenant not to sue provided by this Section 2.3 (i) is a covenant that transfers with any assignment or sale
of, or grant of an exclusive license (with the right to enforce) under, the applicable XOMA Patent Rights by XOMA and (ii) without limiting or expanding the provisions of Section 9.2, shall be binding upon any permitted successors or
assigns of XOMA. XOMA agrees to use commercially reasonable efforts to assist DYAX in recording in a form reasonably acceptable to XOMA the covenant not to sue provided by this Section 2.3, as permitted, with the U.S. Patent and Trademark
Office. The covenant not to sue provided by this Section 2.3: 
  

	 	(a)	shall not extend to the use of the XOMA Expression Technology to make any amount of a Licensed Immunoglobulin or Product other than Research Quantities; provided, however,
that this limitation shall not preclude the manufacture, in commercial quantities, of a Licensed Immunoglobulin discovered using the XOMA Expression Technology in accordance with this Agreement when produced in a production system other than a
prokaryote; 

  

 -7- 









	 	(b)	is personal to DYAX, such Development Partner of DYAX and such DYAX Collaborator and cannot be assigned or transferred; 

  

	 	(c)	does not constitute a release or waiver of past, present or future infringement of the XOMA Patent Rights or misappropriation of the XOMA Know-How by DYAX or any Third Party,
including, without limitation, any DYAX Collaborator acting outside of the scope of the written agreement with DYAX provided for in Section 2.5; and 

  

	 	(d)	shall become void and without effect as to any entity or person who claims its benefit but fails to materially discharge or comply with any term of its written agreement with DYAX
provided for in Section 2.5. 

 2.4 No Implied Rights. Only the rights and licenses granted pursuant to the express
terms of this Agreement shall be of any legal force or effect. No license or other rights shall be deemed to have been granted to DYAX, a Development Partner of DYAX or a DYAX Collaborator other than as expressly provided for in this Agreement. For
the avoidance of doubt, the grants of rights made pursuant to Sections 2.1 and 2.3 do not include, and expressly exclude, the following: 
  

	 	(a)	any right or license under the XOMA Patent Rights and the XOMA Know-How to engage in any activities on behalf of or in collaboration with any Third Party, other than a Development
Partner of DYAX or a DYAX Collaborator; 

  

	 	(b)	any right or license under the XOMA Patent Rights and the XOMA Know-How to use the XOMA Expression Technology to make or have made any amount of a Licensed Immunoglobulin or Product
other than Research Quantities; provided, however, that DYAX or, as applicable, a DYAX Collaborator shall be permitted to make or have made any Licensed Immunoglobulin by any means of its selection other than those which otherwise infringe a
Valid Claim of the XOMA Patent Rights or utilize the XOMA Know-How; and/or 

  

	 	(c)	any right to release any Third Party, including a Development Partner of DYAX or a DYAX Collaborator, from any claim of infringement under the XOMA Patent Rights.


 2.5 Transfer Restrictions. 
 (a) DYAX shall not undertake any Antibody Phage Display activities on behalf of a Third Party or Dispose of Licensed Antibody Phage
Display Materials or the product of the practice of any method within the scope of the XOMA Patents (“Transferred Materials”) to any Third Party until such time as such Third Party has entered into a written agreement with DYAX
pursuant to which such Third Party acknowledges and expressly agrees: 
  

 -8- 









	 	(i)	that the “first sale” doctrine does not apply to any such Disposition; 

  

	 	(ii)	to further Dispose of Transferred Materials only to a Third Party who otherwise meets the definition of a Development Partner or DYAX Collaborator and who executes a written
agreement in which its undertakes all of the obligations applied to the transferring party, provided, however, that this Section 2.5(a)(ii) shall not apply to the Disposition of any Licensed Immunoglobulin where such Third Party
is not a Dyax Development Partner and no royalty is or will otherwise be due under Section 4.1; 

  

	 	(iii)	that the covenant not to sue provided by Section 2.3 does not extend use of the XOMA Expression Technology to make any amount of a Licensed Immunoglobulin or Product other than
Research Quantities; 

  

	 	(iv)	that the covenant not to sue provided by Section 2.3 does not constitute a release or waiver of past, present or future infringement of the XOMA Patent Rights or
misappropriation of the XOMA Know-How by such Third Party; 

  

	 	(v)	that the covenant not to sue provided by Section 2.3 shall be subject to such Third Party’s compliance with Section 8.4; 

  

	 	(vi)	that the covenant not to sue provided by Section 2.3 is personal to such Third Party (as a DYAX Collaborator or DYAX Development Partner) and cannot be assigned or transferred;


  

	 	(vii)	that the covenant not to sue provided by Section 2.3 shall become void and without effect as to any entity or person who claims its benefit but fails to materially discharge or
comply with the foregoing provisions; and 

  

	 	(viii)	that XOMA shall be an intended third party beneficiary with respect to the foregoing provisions. 

 (b) Without expanding or limiting the scope of the licenses and covenants not to sue granted by this Agreement, the provisions of
Section 2.5(a) requiring a written agreement prior to any Disposition of any Transferred Materials shall not apply to a transfer of (i) a Licensed Immunoglobulin discovered by Dyax to a Third Party who is not a Dyax Development Partner
where the making, selling, offering for sale, importing or exporting of such Licensed Immunoglobulin will occur under conditions which will not give rise to any obligation to pay XOMA any royalties under Section 4.1, or (ii) a Licensed
Immunoglobulin discovered exclusively by Dyax to any Third Party where such Disposition is made pursuant to a bona fide material transfer agreement that confers no commercial rights to such Third Party for the sole purpose of permitting such Third
Party to evaluate the transferred Licensed Immunoglobulin; provided, however, that upon the execution of any subsequent agreement relating to such Licensed Immunoglobulin, as applicable, the provisions of Section 2.5(a) shall be
incorporated therein. 
  

 -9- 








 2.6 Reports, Records and Audits. 
 (a) Thirty (30) days after the end of each calendar quarter, commencing with the first calendar quarter commencing after the
Effective Date of the Original Agreement, DYAX shall deliver to XOMA a written report which shall specify the name, address and contact person for each and every DYAX Collaborator and any person or entity receiving Licensed Antibody Phage Display
Materials or a Licensed Immunoglobulin. The reports delivered by DYAX to XOMA pursuant to this Section 2.6(a) shall be Confidential Information of DYAX. 
 (b) Not later than thirty (30) days after the end of each calendar year, commencing with the first calendar year to commence after
the Effective Date of the Original Agreement, as and to the extent publicly disclosed by DYAX (whether in press releases, government filings or otherwise), DYAX shall deliver to XOMA written materials pertaining to the current status of activities
or compositions of matter as to which DYAX claims the right of license hereunder. 
 (c) DYAX shall maintain records fully and
properly reflecting those activities to be reported to XOMA pursuant to Sections 2.6(a) and (b) (the “Records”), in sufficient detail and in good scientific manner appropriate for patent, regulatory and manufacturing purposes
for at least three (3) years. Upon the written request of XOMA and not more than once in each calendar year, DYAX shall permit an independent consultant appointed by XOMA, at XOMA’s expense, to have access during normal business hours to
such of the records of DYAX as may be reasonably necessary to verify compliance with the terms of this Agreement, as well as the accuracy of the reports hereunder. DYAX shall certify any statements by DYAX personnel as to their accuracy and
correctness. The consultant shall not be permitted to see or receive any specific information concerning targets or antibodies of either DYAX or any of its collaborators and shall disclose to XOMA only the results and conclusions of its review and
the specific details concerning any discrepancies. No other information shall be shared by the consultant without the prior consent of DYAX unless disclosure is required by law, regulation or judicial order. 
 2.7 Ownership; Enforcement. At all times XOMA will retain ownership of the XOMA Patent Rights and may use and commercialize such XOMA Patent
Rights itself or with any Third Party. XOMA retains the right, at its sole discretion, to enforce, maintain and otherwise protect the XOMA Know-How and the XOMA Patent Rights. In addition to the requirements of Section 2.6, DYAX shall give XOMA
prompt notice of any infringement of any of the XOMA Patent Rights by a Third Party engaging in a Commercial Antibody Phage Display Business which comes to DYAX’s attention during the term of this Agreement. DYAX will reasonably cooperate with
XOMA with respect to any actions XOMA may choose to take related to the enforcement, maintenance or protection of the XOMA Patent Rights. 
 2.8 Oppositions and/or Appeals to Oppositions. DYAX hereby agrees not to enter into any opposition to and/or appeal from any decision by the patent authorities of any country on the XOMA Patent Rights and shall not assist or
otherwise cooperate with another party in any such opposition or appeal. 
  

 -10- 








 2.9 Release From Past Infringement. XOMA releases DYAX from any claims, demands, and rights of
action arising out of and/or based upon any act or omission committed by DYAX prior to the Effective Date of the Original Agreement, including, without limitation, claims of infringement under the XOMA Patent Rights (the “Release”)
and XOMA releases those Third Parties identified upon Schedule 2.9(i) from any claims, demands, and rights of action arising out of and based upon any infringement of the XOMA Patent Rights (the “Third Party Release”):
provided, however, that the Release and Third Party Release provided for in this Section 2.9 shall extend only to claims, demands or rights of action existing as of the Effective Date of the Original Agreement and which arose solely out
of those activities specified in Schedule 2.9(ii). Nothing in this Section 2.9 shall be deemed to be a release of any claim, demand or right of action XOMA may now or in the future have against [*] or any other entity or person engaged
in a Commercial Antibody Phage Display Business or any of their collaborators (except, in the case of any such collaborator that is also a collaborator of DYAX, to the extent such collaborator’s activities with DYAX are directly and exclusively
within the scope of the Third Party Release). The Release and the Third Party Release shall become irrevocable only upon receipt by XOMA of payment in full by DYAX of all installments of the amounts set forth in Section 4.1 and shall be revoked
in their entirety and null and void ab initio, immediately and without further action of the parties, in the event any installment of such amounts is not received by XOMA on or prior to the fifteenth day following written notice to DYAX from
XOMA of DYAX’s breach in the payment of the full amount of such installment on or prior to the payment date for such installment as set forth in Section 4.1, regardless of any payment received thereafter. 
 ARTICLE 3. DYAX GRANT OF RIGHTS TO XOMA 
 3.1 License Grants. Subject to the other terms and conditions of this Agreement, DYAX hereby grants to XOMA, on its own behalf and on behalf of its Development Partners, a fully paid up, non-exclusive, royalty-free, worldwide license
under the DYAX Patent Rights, to discover, isolate, optimize, develop, offer to use, use, offer for sale, sell, make, have made, export and import Immunoglobulins or products containing or comprising an Immunoglobulin in the XOMA Field of Use,
including without limitation the right to conduct phage display under the DYAX Patent Rights but excluding the conduct of phage display as a Commercial Antibody Phage Display Business. XOMA shall not have the right to sublicense its license rights
under the DYAX Patent Rights to any Third Party. XOMA may not transfer to any Third Party any phage display library the use of which by XOMA is otherwise licensed hereunder if the use thereof by such Third Party would infringe a Valid Claim of the
DYAX Patent Rights. For the avoidance of doubt, nothing herein is intended to prevent XOMA from transferring any Immunoglobulin or any product containing or comprising an Immunoglobulin to a Development Partner of XOMA or a Third Party working on
behalf of XOMA or a Development Partner of XOMA to make, have made, use, sell, have sold and import products, provided that the use of such Immunoglobulin or product by the Development Partner or Third Party does not infringe a Valid Claim of
the DYAX Patent Rights. XOMA is licensed hereby to use phage display materials, including without limitation phage display libraries, received from any Third Party, free from any contractual obligations or limitations otherwise applicable thereto,
so long as XOMA otherwise abides by the terms and conditions of this Agreement. Any use of such phage display materials by XOMA shall be governed in all respects by the provisions of this Agreement and not the provisions of any agreements between
DYAX and any Third Party providing phage 

  

 -11- 








 
display materials to XOMA. Furthermore, for the avoidance of doubt, solely within the XOMA Field of Use, DYAX grants to XOMA, consistent with the other terms
and conditions of this Agreement, a fully paid-up, non-exclusive, royalty-free worldwide right and license to use the DYAX Materials (as defined below). 
 3.2 Covenant Not To Sue. DYAX covenants that it shall not initiate or permit any Third Party over whom it has control to initiate or assist in any way in the initiation or prosecution of any action asserting a
claim of infringement under the DYAX Patent Rights against XOMA or any Development Partner of XOMA or misappropriation of the DYAX Materials against XOMA solely to the extent such claims arise out of (a) use of the DYAX Materials by XOMA as
permitted under the provisions of this Agreement or (b) the discovery, isolation, optimization or development by XOMA, or the manufacture, use, offer for use, sale, offer for sale, importation and exportation, of any Immunoglobulin or product
containing or comprising an Immunoglobulin which were discovered under conditions which but for this license would constitute misappropriation or infringement of the DYAX Patent Rights. 
 3.3 DYAX Transfer to XOMA. 
 (a) DYAX has previously transferred to XOMA, under the terms of the Original Agreement, all of the materials, including without limitation the Licensed Antibody Phage Display Materials, specified on Schedule 3.3 of the Original
Agreement. Within thirty (30) days after the Effective Date of this Agreement, DYAX shall transfer to XOMA those additional Licensed Antibody Phage Display Materials specified on Schedule 3.3 hereof. Collectively, the Licensed Antibody
Phage Display Materials delivered to XOMA under the Original Agreement and those additional Licensed Antibody Phage Display Materials delivered hereunder, are referred to herein as the “DYAX Materials.” XOMA will be able to consult
with DYAX scientific staff at $2,500/person-day (based on an eight hour day) in the use of the DYAX Materials. The cost of all reasonable travel-related expenses will be fully reimbursed to DYAX by XOMA. The DYAX Materials shall be Confidential
Information subject to Article 5. For the avoidance of doubt, all activities of XOMA using the DYAX Materials on or after the Effective Date of this Agreement shall be subject to the provisions of this Agreement and not the Original Agreement.

 (b) DYAX represents and warrants that the DYAX Materials comprise the Licensed Antibody Phage Display Materials, including
the know-how and protocols for using such Licensed Antibody Phage Display Materials, that DYAX customarily provides to licensees of antibody phage display libraries for screening purposes. 
 3.4 Ownership: Enforcement. At all times DYAX will retain ownership or control of the DYAX Patent Rights and may use and commercialize such DYAX
Patent Rights itself or with any Third Party. DYAX retains the right, at its sole discretion, to enforce, maintain and otherwise protect the DYAX Patent Rights. XOMA will reasonably cooperate with DYAX with respect to any actions DYAX may choose to
take related to the enforcement, maintenance or protection of the DYAX Patent Rights. 
 3.5 Oppositions and/or Appeals to
Oppositions. XOMA hereby agrees not to enter into any oppositions to and/or appeal from any decision by the patent authorities of any country on the DYAX 

  

 -12- 








 
Patent Rights and shall not assist or otherwise cooperate with another party in any such opposition or appeal. 
 ARTICLE 4. PAYMENTS 
 4.1
Technology Access and Release Fee. In consideration for the rights granted to DYAX and DYAX Collaborators pursuant to Sections 2.1, 2.2, 2.3 and 2.9, DYAX has previously paid to XOMA, under the terms of the Original Agreement, a fee of Three
Million Five Hundred Thousand United States Dollars (US$3,500,000). XOMA hereby acknowledges receipt of such amount. To the extent that DYAX requires any further assistance in connection with the transfer of XOMA Expression Technology hereunder,
DYAX will be able to consult with XOMA scientific staff at $2,500/person-day (based on an eight hour day). The cost of all reasonable travel-related expenses will be fully reimbursed to XOMA by DYAX. 
 4.2 Royalties. 
 (a)
During the term of this Agreement, DYAX shall pay to XOMA a royalty in cash equal to [*] percent ([*]%) of the Net Sales of any Product(s) in each calendar quarter, commencing with the first calendar quarter ending after the Effective Date of the
Original Agreement. Notwithstanding the foregoing, no royalty shall be payable on Net Sales by or on behalf of a DYAX Collaborator that is not a Development Partner of DYAX where neither DYAX nor any Development Partner of DYAX directly or
indirectly sells the Product. 
 (b) Royalties due under this Article 4 shall be payable on a country-by-country and
Product-by-Product basis from the First Commercial Sale of such Product until the expiration of the last-to-expire XOMA Patent Right in such country with respect to which a Valid Claim covers the manufacture, use, sale, offer for sale, import or
export of such Product or the tenth anniversary of such First Commercial Sale, whichever is later. 
 4.3 Commercially Reasonable
Efforts. DYAX will use its commercially reasonable efforts to exploit the XOMA Patent Rights, generate and use Licensed Antibody Phage Display Materials, conduct Antibody Phage Display, discover, identify, characterize, develop and commercially
launch Licensed Immunoglobulins and Products and/or maximize the amounts available to be shared with XOMA pursuant to this Article 4. DYAX shall also use commercially reasonable efforts to collect or receive any payments or other consideration due
to it relating to any activities that would give rise to an obligation under Section 4.2. 
 4.4 Payments; Currency. All payments
due hereunder shall be paid by wire transfer in United States dollars in immediately available funds to an account designated by XOMA. Payments required pursuant to Section 4.2 hereof shall be due and payable to XOMA when the corresponding Net
Sales are received by DYAX (or any joint venture or similar arrangement in which DYAX is a participant) and shall be paid within thirty (30) days of the end of each calendar quarter. If any currency conversion shall be required in connection
with the payment of any royalties hereunder, such conversion shall be made by 

  

 -13- 








 
using the exchange rate for the purchase of U.S. dollars quoted in the U.S. version of the Wall Street Journal on the last business day of the calendar
quarter to which such payments relate. 
 4.5 Payment Reports. After the First Commercial Sale of a Product on which royalties are
required to be paid hereunder, DYAX shall make quarterly written reports to XOMA within thirty (30) days after the end of each calendar quarter, stating in each such report, by country, the number, description, and aggregate Net Sales of each
Product sold during the calendar quarter. XOMA shall treat all such reports as Confidential Information of DYAX. Concurrently with the making of such reports, DYAX shall pay XOMA the amounts specified in Section 4.2 hereof. 
 4.6 Payment Records and Inspection. DYAX shall keep complete, true and accurate books of account and records for the purpose of determining the
amounts payable under this Agreement. Such books and records shall be kept at the principal place of business of DYAX for at least three (3) years following the end of the calendar quarter to which they pertain. Upon the written request of XOMA
and not more than once in each calendar year, DYAX shall permit an independent consultant appointed by XOMA and reasonably acceptable to DYAX to have access during normal business hours to such of the records of DYAX as may be reasonably necessary
to verify the accuracy of the royalty reports hereunder for any year ending not more than thirty-six (36) months prior to the date of such request, unless a discrepancy is found. The consultant shall disclose to XOMA only the results and
conclusions of its review and the specific details concerning any discrepancies. No other information shall be shared by the consultant without the prior consent of DYAX unless disclosure is required by law, regulation or judicial order. The
consultant may be obliged to execute a reasonable confidentiality agreement prior to commencing any such inspection. Inspections conducted under this Section 4.6 shall be at the expense of XOMA, unless an underpayment exceeding five percent
(5%) of the amount stated for the full period covered by the inspection is identified, in which case all out-of-pocket costs relating to the inspection will be paid promptly by DYAX. Any underpayments or unpaid amounts discovered by such
inspections or otherwise will be paid promptly by DYAX, with interest from the date(s) such amount(s) were due at a rate equal to the lesser of the prime rate reported by the Bank of America plus two percent (2%) or the highest interest rate
permitted under applicable law. 
 ARTICLE 5. CONFIDENTIALITY 
 5.1 Confidential Information. Except as expressly provided herein, the parties agree that, for the term of this Agreement and for five
(5) years thereafter, the receiving party shall keep completely confidential and shall not publish or otherwise disclose and shall not use for any purpose except for the purposes contemplated by this Agreement any Confidential Information
furnished to it by the disclosing party hereto, except to the extent that it can be established by the receiving party by written proof that such Confidential Information: 
  

	 	(a)	was already known to the receiving party, other than under an obligation of confidentiality, at the time of disclosure; 

  

 -14- 









	 	(b)	was generally available to the public or otherwise part of the public domain at the time of its disclosure to the receiving party; 

  

	 	(c)	became generally available to the public or otherwise part of the public domain after its disclosure other than through any act or omission of the receiving party in breach of this
Agreement; or 

  

	 	(d)	was subsequently lawfully disclosed to the receiving party by a person other than a party hereto. 

 5.2 Permitted Use and Disclosures. Each party hereto may use or disclose information disclosed to it by the other party to the extent such use or
disclosure is reasonably necessary in complying with applicable law or government regulations or conducting clinical trials; provided, however, that if a party is required to make any such disclosure of another party’s Confidential
Information, other than pursuant to a confidentiality agreement, it will give reasonable advance notice to the latter party of such disclosure and, will use its reasonable efforts to secure confidential treatment of such information prior to its
disclosure (whether through protective orders or otherwise). Attached hereto as Schedule 5.2 is a redacted copy of this Agreement which DYAX shall be free, without obtaining any consent from XOMA, to provide to Third Parties who indicate an
interest in becoming a DYAX Collaborator or a Development Partner of DYAX. 
 5.3 Confidential Terms. Except as expressly provided
herein, each party agrees not to disclose any terms of this Agreement to any Third Party without the consent of the other party; provided, that disclosures may be made as required by securities or other applicable laws, or to a party’s
accountants, attorneys and other professional advisors. 
 ARTICLE 6. REPRESENTATIONS AND WARRANTIES 
 6.1 Representations and Warranties. 
  

	 	(a)	XOMA represents and warrants to DYAX that: (i) it is the sole and exclusive owner or exclusive licensee of all right, title and interest in the XOMA Patent Rights;
(ii) XOMA has the legal right, authority and power to enter into this Agreement; (iii) this Agreement shall constitute a valid and binding obligation of XOMA enforceable in accordance with its terms; and (iv) the performance of
obligations under this Agreement by XOMA shall not result in a breach of any agreements, contracts or other arrangements to which it is a party. 

  

	 	(b)	DYAX represents and warrants to XOMA that: (i) it is the sole and exclusive owner or exclusive licensee of all right, title and interest in the DYAX Patent Rights,
(ii) DYAX has the legal right, authority and power to enter into this Agreement; (iii) this Agreement shall constitute a valid and binding obligation of DYAX enforceable in accordance with its terms; and (iv) the performance of
obligations under this Agreement by DYAX shall not result in a breach of any agreements, contracts or other arrangements to which it is a party. 

  

 -15- 








 6.2 Disclaimer. Nothing in this Agreement is or shall be construed as: 
  

	 	(a)	A warranty or representation by XOMA or DYAX as to the validity or scope of any claim or patent within the XOMA Patent Rights or the DYAX Patent Rights, as the case may be;


  

	 	(b)	A warranty or representation that anything made, used, sold, or otherwise disposed of under any license granted in this Agreement is or will be free from infringement of any patent
rights or other intellectual property right of any Third Party; 

  

	 	(c)	An obligation to bring or prosecute actions or suits against Third Parties for infringement of any of the XOMA Patent Rights or the DYAX Patent Rights; 

  

	 	(d)	An obligation to maintain any patent or to continue to prosecute any patent application included within the XOMA Patent Rights or the DYAX Patent Rights in any country; or


  

	 	(e)	Granting by implication, estoppel, or otherwise any licenses or rights under patents or other rights of XOMA, DYAX or Third Parties, regardless of whether such patents or other
rights are dominant or subordinate to any patent within the XOMA Patent Rights or the DYAX Patent Rights, as the case may be. 

 6.3 No Other Warranties. EXCEPT AS OTHERWISE SET FORTH IN SECTION 6.1 ABOVE, NEITHER PARTY HERETO MAKES ANY WARRANTIES WITH RESPECT TO ANY OF THE PATENT RIGHTS, MATERIALS OR KNOW-HOW LICENSED HEREUNDER, EXPRESS OR IMPLIED, EITHER IN
FACT OR BY OPERATION OF LAW, BY STATUTE OR OTHERWISE, AND EACH PARTY SPECIFICALLY DISCLAIMS ANY EXPRESS OR IMPLIED WARRANTY OF MERCHANTABILITY, OF FITNESS FOR A PARTICULAR PURPOSE, OF VALIDITY OF SUCH PATENT RIGHTS, MATERIALS OR KNOW-HOW, ARISING
FROM COURSE OF DEALING OR OF NON-INFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS OF ANY THIRD PARTY. 
 6.4 Certain Agreements. DYAX
represents and warrants that it has in its possession, and agrees that throughout the term of this Agreement it will maintain in an accessible location, true, complete and legible copies of each of the agreements set forth on Schedule 2.9 as in
effect on the Effective Date of the Original Agreement, including all schedules, exhibits and other similar documents necessary for the correct interpretation of the provisions thereof. 
  

 -16- 








 ARTICLE 7. [RESERVED] 
 ARTICLE 8. TERM AND TERMINATION 
 8.1 Term. Subject to Sections 8.5 and 8.6 hereof, the term
of this Agreement will commence on the Effective Date and (a) with regard to the license rights granted to XOMA by DYAX pursuant to Article 3, this Agreement shall remain in full force and effect until the last to expire of the DYAX Patent
Rights, unless earlier terminated by DYAX pursuant to Section 8.2, 8.3 or 8.4; provided, however, that upon such expiration and absent any earlier termination pursuant to Section 8.2, 8.3 or 8.4, XOMA shall have a royalty-free,
fully paid up right and license to continue to use the DYAX Materials as permitted by Article 3; and (b) with regard to the license and other rights granted to DYAX and any DYAX Collaborators or Development Partners of DYAX by XOMA pursuant to
Article 2, this Agreement shall remain in full force and effect until the last to expire of the XOMA Patent Rights or the tenth anniversary of the First Commercial Sale of the last Product to be launched, whichever is later, unless earlier
terminated by XOMA pursuant to Section 8.2, 8.3 or 8.4; provided, however, that, to the extent any of the XOMA Know-How is not included in the XOMA Patent Rights, upon such expiration and absent any earlier termination pursuant to
Section 8.2, 8.3 or 8.4, DYAX shall have a royalty-free, fully paid up right and license to continue to use the XOMA Know-How as permitted by Article 2 . 
 8.2 Termination for Material Breach. With regard to (a) the license rights granted to XOMA by DYAX pursuant to Article 3, or (b) the license and other rights granted to DYAX and any DYAX Collaborators
or Development Partners of DYAX by XOMA pursuant to Article 2, this Agreement may be terminated by either DYAX or XOMA upon any material breach by XOMA or DYAX, as the case may be, of any material obligation or condition of the Agreement, in either
case effective fifteen (15) days after giving notice to the breaching party of such termination in the case of a payment breach and sixty (60) days after giving written notice to the breaching party of such termination in the case of any
other breach, which notice shall describe such breach in reasonable detail. The foregoing notwithstanding, if such breach is cured or shown to be non-existent within the aforesaid fifteen (15) or sixty (60) day period, the notice shall be
deemed automatically withdrawn and of no effect and the notifying party shall provide written notice to the breaching party of the withdrawal. A termination of the breaching party’s rights and licenses pursuant to this Section 8.2 shall
not effect the non-breaching party’s rights and licenses, which shall continue until otherwise terminated in accordance with this Agreement. 
 8.3 Termination for Insolvency. If voluntary or involuntary proceedings by or against either party are instituted in bankruptcy under any insolvency law, or a receiver or custodian is appointed for either party, or proceedings are
instituted by or against either party for corporate reorganization or the dissolution of such party, which proceedings, if involuntary, shall not have been dismissed within sixty (60) days after the date of filing, or if either party makes an
assignment for the benefit of creditors, or substantially all of the assets of either party are seized or attached and not released within sixty (60) days thereafter, the other party may immediately terminate this Agreement effective upon
notice of such termination. 
 8.4 Contested Validity. If DYAX, a DYAX Collaborator or any person or entity controlled by any of the
foregoing contests the validity or enforceability of any of the XOMA Patent Rights licensed hereunder, XOMA shall have the right to terminate all of the rights and licenses hereby granted to DYAX and any DYAX Collaborator under the XOMA Patent
Rights; provided, however, that in the event a DYAX Collaborator contests the validity or enforceability of any of the XOMA Patent Rights licensed 

  

 -17- 








 
hereunder other than at the direction, and without the assistance or other involvement, of DYAX, then the foregoing termination right of XOMA shall apply
only to the rights hereby granted to such DYAX Collaborator. If XOMA or any person or entity controlled by XOMA contests the validity or enforceability of any of the DYAX Patent Rights licensed hereunder, DYAX shall have the right to terminate all
of the rights and licenses hereby granted to XOMA under the DYAX Patent Rights. 
 8.5 Effect of Termination. 
 (a) Termination of this Agreement shall not release any party hereto from any liability which, at the time of such termination, has
already accrued to the other party or which is attributable to a period prior to such termination nor preclude either party from pursuing any rights and remedies it may have hereunder or at law or in equity with respect to any breach of this
Agreement. It is understood and agreed that monetary damages may not be a sufficient remedy for any breach of this Agreement and that the non-breaching party may be entitled to injunctive relief as a remedy for any such breach. Such remedy shall not
be deemed to be the exclusive remedy for any such breach of this Agreement, but shall be in addition to all other remedies available at law or in equity. 
 (b) Upon any termination of this Agreement, DYAX and XOMA shall promptly return to the other party all Confidential Information received from the other party (except that each party may retain one copy for its files
solely for the purpose of determining its rights and obligations hereunder). 
 (c) Except as expressly provided in Sections
8.1 and 8.2, all licenses granted under Article 2 hereof shall terminate and be of no further effect upon the termination of this Agreement. 
 8.6 Survival. Sections 2.6(c), 2.7, 2.8, 2.9, 3.3, 3.4, 3.5, 4.2, 4.4, 4.5, 4.6, 8.2, 8.5 and 8.6, and Articles 1, 5, 6 and 9 of this Agreement shall survive any termination hereof. Without limiting the foregoing, Article 2 of this
Agreement shall survive any termination hereof by DYAX, and Article 3 of this Agreement shall survive any termination hereof by XOMA. 
 ARTICLE 9. MISCELLANEOUS PROVISIONS 
 9.1 Governing Laws. This Agreement and any dispute, including without
limitation any arbitration, arising from the performance or breach hereof shall be governed by and construed and enforced in accordance with the laws of the state of New York, without reference to conflicts of laws principles. 
 9.2 Assignment. Neither party may transfer or assign this Agreement, directly or indirectly, or any of its rights hereunder without the prior
written consent of the other party, other than (a) to one or more Affiliates, (b) to a successor of XOMA Ltd. under a Change in Control of XOMA Ltd. or to a successor of DYAX Corp. under a Change in Control of DYAX Corp. to which
Section 9.3 does not apply, or (c) to a Third Party in connection with the transfer or sale of all or substantially all or its business relating to antibody selection, development and production and the provision of related services (other
than (i) with respect to such a transfer or sale by DYAX, such a transfer or sale to any Person listed or described in Section 9.3 and (ii) with respect to such a transfer or sale by XOMA, such a transfer or sale to [*]. Any 

  

 -18- 








 
such attempted transfer or assignment in violation of this Section 9.2 shall be void; provided, that in the event of a permitted Change in
Control, the original party’s (or its successor’s) obligations hereunder shall continue. This Agreement shall be binding upon and inure to the benefit of the parties and their permitted successors and assigns. 
 9.3 Certain Changes in Control. Notwithstanding any other provision of this Agreement to the contrary, the license and other rights granted
pursuant to Article 2 shall automatically terminate, without further action by the parties, in the event of (a) a transaction or series of related transactions in which [*] is a party and which results in a Change of Control of DYAX, or
(b) a transaction or series of related transactions in which DYAX is a party and which results in a Change in Control of a person or entity described in clause (a) above. 
 9.4 Waiver. No waiver of any rights shall be effective unless consented to in writing by the party to be charged and the waiver of any breach or
default shall not constitute a waiver of any other right hereunder or any subsequent breach or default. 
 9.5 Severability. In the
event that any provisions of this Agreement are determined to be invalid or unenforceable by a court of competent jurisdiction, the remainder of the Agreement shall remain in full force and effect without said provision. 
 9.6 Notices. All notices, requests and other communications hereunder shall be in writing and shall be delivered or sent in each case to the
respective address specified below, or such other address as may be specified in writing to the other party hereto, and shall be effective on receipt: 
  

			
	 DYAX:
	  	DYAX Corp.
		  	300 Technology Square
		  	Cambridge, MA 02139
		  	U.S.A.
		  	Attn: General Counsel
		
	 XOMA:
	  	XOMA Ireland Limited
		  	Shannon Airport House
		  	Shannon, County Clare
		  	Ireland
		  	Attn: Company Secretary
	
	 with a copy (which shall not constitute notice) to:

		
		  	Cahill Gordon & Reindel LLP
		  	80 Pine Street
		  	New York, NY 10005
		  	U.S.A.
		  	Attn: Geoffrey E. Liebmann

  

 -19- 








 9.7 Independent Contractors. Both parties are independent contractors under this Agreement.
Nothing contained in this Agreement is intended nor is to be construed so as to constitute XOMA or DYAX as partners or joint venturers with respect to this Agreement. Except as expressly provided herein, neither party shall have any express or
implied right or authority to assume or create any obligations on behalf of or in the name of the other party or to bind the other party to any other contract, agreement, or undertaking with any third party. 
 9.8 Compliance with Laws. In exercising their rights under this license, the parties shall comply in all material respects with the requirements
of any and all applicable laws, regulations, rules and orders of any governmental body having jurisdiction over the exercise of rights under this Agreement. 
 9.9 Bankruptcy. All rights and licenses granted under or pursuant to this Agreement by one party to the other are, for all purposes of Section 365(n) of Title XI of the United States Code (“Title
XI”), licenses of rights to “intellectual property” as defined in Title XI. During the term of this Agreement each party shall create and maintain current copies to the extent practicable of all such intellectual property. If a
bankruptcy proceeding is commenced by or against one party under Title XI, the other party shall be entitled to a copy of any and all such intellectual property and all embodiments of such intellectual property, and the same, if not in the
possession of such other party, shall be promptly delivered to it (a) upon such party’s written request following the commencement of such bankruptcy proceeding, unless the party subject to such bankruptcy proceeding, or its trustee or
receiver, elects within thirty (30) days to continue to perform all of its obligations under this Agreement, or (b) if not delivered as provided under clause (a) above, upon such other party’s request following the rejection of
this Agreement by or on behalf of the party subject to such bankruptcy proceeding. If a party has taken possession of all applicable embodiments of the intellectual property of the other party pursuant to this Section 9.9 and the trustee in
bankruptcy of the other party does not reject this Agreement, the party in possession of such intellectual property shall return such embodiments upon request. If a party seeks or involuntarily is placed under Title XI and the trustee rejects this
Agreement as contemplated under 11 U.S.C. 365(n)(1), the other party hereby elects, pursuant to Section 365(n) of Title XI, to retain all rights granted to it under this Agreement to the extent permitted by law. 
 9.10 Use of Name. Neither party shall use the name or trademarks of the other party, except to the extent that a party is permitted to use the
Confidential Information of the other party pursuant to Article 5, without the prior written consent of such other party. 
 9.11 Further
Actions. Each party agrees to execute, acknowledge and deliver such further instruments, and do such other acts, as may be necessary and appropriate in order to carry out the purposes and intent of this Agreement. 
 9.12 Entire Agreement: Amendment. This Agreement, together with the agreement of XOMA contained in that certain letter agreement, dated
July 24, 2006 (which agreement shall also have effect with respect to this Agreement), constitutes the entire and exclusive Agreement between the parties with respect to the subject matter hereof and supersedes and cancels all previous
discussions, agreements, 

  

 -20- 








 
commitments and writings in respect thereof. No amendment or addition to this Agreement shall be effective unless reduced to writing and executed by the
authorized representatives of the parties. 
 9.13 Arbitration. 
 (a) Solely with respect to any dispute between the parties to this Agreement (other than any dispute which arises out of or relates to
infringement, validity and/or enforceability of the XOMA Patent Rights or the DYAX Patent Rights) upon ten (10) days written notice, any party involved in the dispute may initiate arbitration by giving notice to that effect to the other party
or parties involved in the dispute and by filing the notice with the American Arbitration Association or its successor organization (“AAA”) in accordance with its Commercial Arbitration Rules. Such dispute shall then be settled by
arbitration in New York, New York, in accordance with the Commercial Arbitration Rules of the AAA or other rules agreed to by the parties involved in the dispute, by a panel of three neutral arbitrators, who shall be selected by the parties involved
in the dispute using the procedures for arbitrator selection of the AAA. 
 (b) The parties acknowledge that this Agreement
evidences a transaction involving interstate commerce. Insofar as it applies, the United States Arbitration Act shall govern the interpretation of, enforcement of, and proceedings pursuant to the arbitration clause in this Agreement. Except insofar
as the United States Arbitration Act applies to such matters, the agreement to arbitrate set forth in this Section 9.13 shall be construed, and the legal relations among the parties shall be determined in accordance with, the substantive laws
of the State of New York. 
 (c) The panel shall render its decision and award, including a statement of reasons upon which
such award is based, within thirty (30) days after the arbitration hearing. The decision of the panel shall be determined by majority vote among the arbitrators, shall be in writing and shall be binding upon the parties involved in the dispute,
final and non-appealable. Judgment upon the award rendered by the panel may be entered in any court having jurisdiction thereof in accordance with Section 9.14(a). 
 (d) Except as provided under the United States Arbitration Act and with respect to the infringement, validity and/or enforceability of the
XOMA Patent Rights or the DYAX Patent Rights, no action at law or in equity based upon any dispute that is subject to arbitration under this Section 9.13 shall be instituted. 
 (e) All expenses of any arbitration pursuant to this Section 9.13, including fees and expenses of the parties’ attorneys, fees
and expenses of the arbitrators, and fees and expenses of any witness or the cost of any proof produced at the request of the arbitrators, shall be paid by the non-prevailing party. 
 9.14 Venue; Jurisdiction. 
 (a) Any action or proceeding brought by either party seeking to enforce any provision of, or based on any right arising out of, this Agreement must be brought against any of the parties in 

  

 -21- 








 
the courts of the State of New York. Each party (i) hereby irrevocably submits to the jurisdiction of the state courts of the State of New York and to
the jurisdiction of any United States District Court in the State of New York, for the purpose of any suit, action, or other proceeding arising out of or based upon this Agreement or the subject matter hereof brought by any party or its successors
or assigns, (ii) hereby waives, and agrees not to assert, by way of motion, as a defense, or otherwise, in any such suit, action, or proceeding, any claim that it is not subject personally to the jurisdiction of the above-named courts, that its
property is exempt or immune from attachment or execution, that the suit, action or proceeding is brought in an inconvenient forum, that the venue of the suit, action, or proceeding is improper or that this Agreement or the subject matter hereof may
not be enforced in or by such court, and (iii) hereby waives and agrees not to seek any review by any court of any other jurisdiction that may be called upon to grant an enforcement of the judgment of any such New York state or federal court.

 (b) Process in any action or proceeding seeking to enforce any provision of, or based on any right arising out of, this
Agreement may be served on any party anywhere in the world. Each party consents to service of process by registered mail at the address to which notices are to be given pursuant to Section 9.6. Nothing herein shall affect the right of a party
to serve process in any other manner permitted by applicable law. Each party further agrees that final judgment against it in any such action or proceeding arising out of or relating to this Agreement shall be conclusive and may be enforced in any
other jurisdiction within or outside the United States of America by suit on the judgment, a certified or exemplified copy of which shall be conclusive evidence of the fact and of the amount of its liability. 
 (c) Each party agrees that it shall not, and that it shall instruct those in its control not to, take any action to frustrate or prevent
the enforcement of any writ, decree, final judgment, award (arbitral or otherwise) or order entered against it with respect to this Agreement, the XOMA Patent Rights or the DYAX Patent Rights and shall agree to be bound thereby as if issued or
executed by a competent judicial tribunal having personal jurisdiction situated in its country of residence or domicile. 
 9.15
Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 
  

 -22- 








 IN WITNESS WHEREOF, XOMA and DYAX have executed this Agreement in duplicate originals by duly authorized
officers. 
  

									
	DYAX CORP.	 		 	XOMA IRELAND LIMITED
					
	By:	 	/s/ IVANA MAGOVCEVIC-LIEBISCH	 		 	By:	 	/s/ ALAN KANE
	Name:	 	Ivana Magovcevic-Liebisch, Ph.D. J.D.	 		 		 	Alan Kane, Director
	Title:	 	General Counsel & Executive Vice President,
Corporate Communications	 		 		 	duly authorized for and on behalf of XOMA Ireland Limited in the presence of:
					
		 		 		 		 	/s/ NIAMH COGHLAN

  

 -23- 








 SCHEDULE 1.9 
 Dyax Patent Rights 
  

											
	 Country
	  	 Application/
Publication No.
	  	Filing Date	  	Patent No.	  	Issue Date	  	Expiration
Date
	 US
	  	07/664,989	  	03/01/91	  	5,223,409	  	06/29/93	  	06/29/10
	 US
	  	08/009,319	  	01/26/93	  	5,403,484	  	04/04/95	  	04/04/12
	 US
	  	08/057,667	  	06/18/93	  	5,571,698	  	11/05/96	  	06/29/10
	 US
	  	08/415,922	  	04/03/95	  	5,837,500	  	11/17/98	  	06/29/10
	 US
	  	09/781,988	  	02/14/01	  	6,979,538	  	12/27/05	  	06/29/10
	 US
	  	09/893,878	  	06/29/01	  		  		  	
	 US
	  	10/126,544	  	04/22/02	  		  		  	
	 US
	  	10/207,797	  	07/31/02	  		  		  	
	 US
	  	08/821,498	  	03/21/97	  	6,326,155	  	12/04/01	  	
	 PCT
	  	 PCT/US89/03731
 W090/02809 (pub)
	  	09/01/89	  		  	National Phase	  	
	 EP
	  	89910702.3	  	09/01/89	  	EP 436,597	  	04//02/97	  	Revoked
	 EP
	  	 Divisional 96/112867.5
 768377 (pub)
	  	09/01/89	  		  		  	Abandoned
	 EP
	  	Divisional 00106289.2	  	09/01/89	  		  		  	Abandoned
	 EP
	  	 Divisional 05000796.2
 EP1541682
	  	09/01/89	  		  		  	Published
	 Japan
	  	 510087/1989
 JP4502700 (pub)
	  	09/01/89	  	3771253	  	02/17/06	  	09/01/09
	 Canada
	  	610,176	  	09/01/89	  	1,340,288	  	01/27/99	  	09/01/09
	 Canada
	  	2105300	  	02/27/92	  	2105300	  	09/02/1992	  	02/27/12
	 Ireland
	  	IR89/2834	  	09/04/89	  		  		  	
	 Israel
	  	91501	  	09/01/89	  	91501	  	06/11/98	  	09/01/09
	 Israel
	  	Divisional 120,941	  	09/01/89	  	120,941	  	09/20/2005	  	09/01/09
	 Israel
	  	Divisional 120,940	  	09/01/89	  	120,940	  	09/20/2005	  	09/01/09
	 Israel
	  	Divisional 120,939	  	09/01/89	  	120,939	  	10/25/2001	  	09/01/09
	 PCT
	  	 US92/01539
 W092/15679 (pub)
	  	02/28/92	  		  	National Phase	  	
	 EP
	  	92/908799.7	  	02/28/92	  	0 573 611	  	03/17/04	  	02/28/12
	 EP
	  	04/006079.0	  	02/28/92	  		  		  	
	 Japan
	  	508216/1992	  	02/28/92	  	3447731	  	07/04/03	  	02/28/12
	 Japan
	  	130929	  	05/09/03	  		  		  	
	 Japan
	  	507558	  	02/27/92	  		  		  	

  

 -24- 








 SCHEDULE 1.24 
 XOMA Patent Rights 
 Title: Modular Assembly of Antibody Genes, Antibodies Prepared Thereby and Use

 Inventors: Robinson, Liu, Horwitz, Wall, Better 
  

	1)	Based on PCT/US86/02269, which is a continuation-in-part of U.S. Application No. 06/793,980 filed November 1, 1985 (abandoned). 

  

					
	 COUNTRY
	  	APPLICATION NO.	  	PATENT NO.
	 Australia
	  	65981/86	  	Issued 606,320
	 Denmark
	  	3385/87	  	Issued PR 175680 B1
	 Taiwan
	  	75105650	  	Expired
	 *United States
	  	06/793,980	  	
	 *United States
	  	U.S. National Phase of
PCT/US86/02269	  	

  

	*	Cases abandoned in favor of a continuing application. 

  

	2)	Based on PCT/US88/02514, which corresponds to U.S. Application No. 07/077,528, which is a continuation-in-part PCT/US86/02269 (abandoned), which is a continuation-in-part of
U.S. Application No. 06/793,980 (abandoned). 

  

					
	 COUNTRY
	  	APPLICATION NO.	  	PATENT NO.
	 Australia
	  	23244/88	  	Issued 632,462
	 Canada
	  	572,398	  	Granted 1,341,235
	 Denmark
	  	192/90	  	Granted 174824
	 Denmark
	  	200301155	  	Granted PR 175654 B1
	 Denmark
	  	200301156	  	Granted PR 175581 B1
	 Europe
	  	EP 88907510.7	  	Granted EP 0371998
	 Austria
	  	EP 88907510.7	  	Granted EP 0371998
	 Belgium
	  	EP 88907510.7	  	Granted EP 0371998
	 France
	  	EP 88907510.7	  	Granted EP 0371998
	 Germany
	  	EP 88907510.7	  	Granted P 3888186.1
	 Italy
	  	EP 88907510.7	  	Granted EP 0371998
	 Luxembourg
	  	EP 88907510.7	  	Granted EP 0371998
	 Netherlands
	  	EP 88907510.7	  	Granted EP 0371998
	 Sweden
	  	EP 88907510.7	  	Granted EP 0371998
	 Switzerland/Liechtenstein
	  	EP 88907510.7	  	Granted EP 0371998
	 United Kingdom
	  	EP 88907510.7	  	Granted EP 0371998
	 Europe
	  	EP 93100041.8	  	Granted EP 0550400
	 Austria
	  	EP 93100041.8	  	Granted EP 0550400
	 Belgium
	  	EP 93100041.8	  	Granted EP 0550400
	 France
	  	EP 93100041.8	  	Granted EP 0550400
	 Germany
	  	EP 93100041.8	  	Granted P 3855421.6
	 Italy
	  	EP 93100041.8	  	Granted EP 0550400
	 Luxembourg
	  	EP 93100041.8	  	Granted EP 0550400

  

 -25- 









					
	 Netherlands
	  	EP 93100041.8	  	Granted EP 0550400
	 Sweden
	  	EP 93100041.8	  	Granted EP 0550400
	 Switzerland/ Liechtenstein
	  	EP 93100041.8	  	Granted EP 0550400
	 United Kingdom
	  	EP 93100041.8	  	Granted EP 0550400
	 Europe
	  	EP 95119798.7	  	Granted EP 0731167
	 Austria
	  	EP 95119798.7	  	Granted EP 0731167
	 Belgium
	  	EP 95119798.7	  	Granted EP 0731167
	 France
	  	EP 95119798.7	  	Granted EP 0731167
	 Germany
	  	EP 95119798.7	  	Granted P 3856440.12
	 Italy
	  	EP 95119798.7	  	Granted EP 0731167
	 Luxembourg
	  	EP 95119798.7	  	Granted EP 0731167
	 Netherlands
	  	EP 95119798.7	  	Granted EP 0731167
	 Sweden
	  	EP 95119798.7	  	Granted EP 0731167
	 Switzerland/ Liechtenstein
	  	EP 95119798.7	  	Granted EP 0731167
	 United Kingdom
	  	EP 95119798.7	  	Granted EP 0731167
	 Japan
	  	506481/88	  	Granted 2991720
	 *United States
	  	07/077,528	  	

  

	*	Cases abandoned in favor of a continuing application. 

  

	3)	Based on U.S. Application No. 07/501,092 filed March 29, 1990, which is a continuation-in-part of U.S. Application No. 07/077,528 (Modular Assembly of Antibody Genes,
Antibodies Prepared Thereby and Use; Robinson, Liu, Horwitz, Wall, Better) and of U.S. Application No. 07/142,039 (Novel Plasmid Vector with Pectate Lyase Signal Sequence; Lei, Wilcox). 

  

					
	 COUNTRY
	  	APPLICATION NO.	  	PATENT NO.
	 *United States
	  	07/501,092	  	
	 *United States
	  	07/987,555	  	
	 *United States
	  	07/870,404	  	
	 *United States
	  	08/020,671	  	
	 *United States
	  	09/722,425	  	Abandoned
	 *United States
	  	09/722,315	  	Abandoned
	 United States
	  	08/235,225	  	5,618,920
	 United States
	  	08/299,085	  	5,595,898
	 United States
	  	08/472,691	  	6,204,023
	 United States
	  	08/467,140	  	5,698,435
	 United States
	  	08/450,731	  	5,693,493
	 United States
	  	08/466,203	  	5,698,417
	 United States
	  	10/040,945	  	Pending

  

	*	Cases abandoned in favor of a continuing application. 

 Title:
AraB Promoters and Method of Producing Polypeptides, Including Cecropins, by Microbiological Techniques 
  

 -26- 








 Inventors: Lai, Lee, Lin, Ray, Wilcox 
 Based on PCT/US86/00131, which is a continuation-in-part of U.S. Application No. 06/695,309 filed January 28, 1985 (abandoned).

  

					
	 COUNTRY
	  	APPLICATION NO.	  	PATENT NO.
	 Europe
	  	EP 86900983.7	  	Granted EP 0211047
	 Austria
	  	EP 86900983.7	  	Granted EP 0211047
	 Belgium
	  	EP 86900983.7	  	Granted EP 0211047
	 France
	  	EP 86900983.7	  	Granted EP 0211047
	 Germany
	  	EP 86900983.7	  	Granted P3689598.9-08
	 Italy
	  	EP 86900983.7	  	Granted EP 0211047
	 Luxembourg
	  	EP 86900983.7	  	Granted EP 0211047
	 Netherlands
	  	EP 86900983.7	  	Granted EP 0211047
	 Sweden
	  	EP 86900983.7	  	Granted EP 0211047
	 Switzerland/ Liechtenstein
	  	EP 86900983.7	  	Granted EP 0211047
	 United Kingdom
	  	EP 86900983.7	  	Granted EP 0211047
	 Finland
	  	863891	  	Granted 94774
	 Japan
	  	500818/86	  	Granted 2095930
	 Japan
	  	094753/94	  	Granted 2121896
	 Norway
	  	863806	  	Granted 175870
	 *United States
	  	06/695,309	  	
	 *United States
	  	06/797,472	  	
	 United States
	  	07/474,304	  	Granted 5,028,530

  

	*	Cases abandoned in favor of a continuing application. 

 Title:
Novel Plasmid Vector with Pectate Lyase Signal Sequence 
 Inventors: Lei, Wilcox 
 Based on U.S. Application No. 07/142,039 filed January 11, 1988 and PCT/US89/00077. 
  

					
	 COUNTRY
	  	APPLICATION NO.	  	PATENT NO.
	 Australia
	  	29377/89	  	Issued/627443
	 Canada
	  	587,885	  	1,338,807
	 Europe
	  	EP 89901763.6	  	Granted EP 0396612
	 Austria
	  	EP 89901763.6	  	Granted EP 0396612
	 Belgium
	  	EP 89901763.6	  	Granted EP 0396612
	 France
	  	EP 89901763.6	  	Granted EP 0396612
	 Germany
	  	EP 89901763.6	  	Granted 689 26 882 T2
	 Italy
	  	EP 89901763.6	  	Granted EP 0396612
	 Luxembourg
	  	EP 89901763.6	  	Granted EP 0396612
	 Netherlands
	  	EP 89901763.6	  	Granted EP 0396612
	 Sweden
	  	EP 89901763.6	  	Granted EP 0396612
	 Switzerland/ Liechtenstein
	  	EP 89901763.6	  	Granted EP 0396612
	 United Kingdom
	  	EP 89901763.6	  	Granted EP 0396612
	 Japan
	  	501661/89	  	Granted 2980626

  

 -27- 









					
	 *United States
	  	07/142,039	  	
	 United States
	  	08/472,696	  	5,846,818
	 United States
	  	08/357,234	  	5,576,195

  

	*	Cases abandoned in favor of a continuing application. 

  

 -28- 








 SCHEDULE 2.2 
 Transfer of XOMA Materials 
 [*] 
  

 -29- 








 SCHEDULE 2.9 
 Third Parties and Activities 
 [*] 
  

 -30- 








 SCHEDULE 3.3 
 Dyax Materials 
 [*] 
  

 -31- 








 SCHEDULE 5.2 
 Redacted Agreement 
  

 -32-